JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Search

CorMedix Inc

Cerrado

SectorSanidad

11.39 -1.21

Resumen

Variación precio

24h

Actual

Mínimo

11

Máximo

11.67

Métricas clave

By Trading Economics

Ingresos

-816K

20M

Ventas

655K

40M

P/B

Media del Sector

14.795

77.256

BPA

0.28

Margen de beneficios

49.898

Empleados

64

EBITDA

-297K

21M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+64.64% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-17M

904M

Apertura anterior

12.6

Cierre anterior

11.39

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

108 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CorMedix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 nov 2025, 23:57 UTC

Ganancias

Naver's Third-Quarter Earnings Rose on AI Push

4 nov 2025, 23:10 UTC

Adquisiciones, fusiones, absorciones

Kennedy-Wilson Gets Acquisition Proposal From CEO, Fairfax Financial

4 nov 2025, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 nov 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Fall After U.S. Tech Stock Weakness -- Market Talk

4 nov 2025, 23:37 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

4 nov 2025, 23:30 UTC

Ganancias

Itau Unibanco 3Q Net BRL33.7B >ITUB

4 nov 2025, 23:25 UTC

Ganancias

Naver 3Q Net Profit Beat FactSet-Compiled Consensus

4 nov 2025, 23:25 UTC

Ganancias

Naver 3Q Net KRW734.70B Vs. Net KRW530.10B >035420.SE

4 nov 2025, 23:24 UTC

Ganancias

Naver 3Q Oper Pft KRW570.60B Vs. Pft KRW525.30B >035420.SE

4 nov 2025, 23:23 UTC

Ganancias

Naver 3Q Rev KRW3.138T Vs. KRW2.716T >035420.SE

4 nov 2025, 23:06 UTC

Ganancias

Review & Preview: Tech Check -- Barrons.com

4 nov 2025, 22:52 UTC

Ganancias

AMD Reports Sharply Higher Profits, Sales -- 3rd Update

4 nov 2025, 22:33 UTC

Ganancias

AMD Beats Earnings. The Stock Still Slides. -- Barrons.com

4 nov 2025, 22:29 UTC

Ganancias

Ashland 4Q Adj EPS $1.08 >ASH

4 nov 2025, 22:29 UTC

Ganancias

Ashland Sees FY26 Adjusted EPS Up More Than Double Digits >ASH

4 nov 2025, 22:28 UTC

Ganancias

Ashland Sees FY26 Sales $1.84B-$1.91B >ASH

4 nov 2025, 22:27 UTC

Ganancias

Ashland 4Q Cont Ops EPS 73c >ASH

4 nov 2025, 22:27 UTC

Ganancias

Ashland 4Q EPS 71c >ASH

4 nov 2025, 22:27 UTC

Ganancias

Ashland 4Q Sales $478M >ASH

4 nov 2025, 22:23 UTC

Ganancias

Ovintiv 3Q EPS 57c >OVV

4 nov 2025, 22:19 UTC

Charlas de Mercado

Canada Budget: Snap Election Talk Might Cool -- Market Talk

4 nov 2025, 22:16 UTC

Ganancias

AMD Reports Sharply Higher Profits, Sales -- 2nd Update

4 nov 2025, 22:14 UTC

Adquisiciones, fusiones, absorciones

Kennedy-Wilson Board Forms Special Committee to Evaluate Proposal

4 nov 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Consortium: Not Interested in Selling Kennedy-Wilson Shares to Another Party

4 nov 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Consortium: Able to Finance a Deal With Available Liquidity

4 nov 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

Consortium Owns About 31% of Kennedy-Wilson Stock on As-Converted Basis

4 nov 2025, 22:11 UTC

Ganancias

Private-Credit Earnings Ease Investor Concern Over Market's Health -- Update

4 nov 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

Kennedy-Wilson Gets Proposal From CEO William McMorrow and Fairfax Financial Holdings

4 nov 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4 nov 2025, 22:07 UTC

Ganancias

Kinross Gold Raises Dividend to $0.035 >K.T

Comparación entre iguales

Cambio de precio

CorMedix Inc previsión

Precio Objetivo

By TipRanks

64.64% repunte

Estimación a 12 Meses

Media 19 USD  64.64%

Máximo 22 USD

Mínimo 14 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CorMedix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.2 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

108 / 373 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat